Laureate Biopharmaceutical Services

Belkins
Gallus BioPharmaceuticals, LLC has been acquired by DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees.

Related News

MEDICAL

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems | September 24, 2021

news image

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More

UK STARTUP SNAPS UP POTENTIAL UNIVERSAL CANCER IMMUNOTHERAPY

Labiotech.eu | January 27, 2020

news image

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Read More

MEDICAL

CONTROLANT NOW PROVIDING MONITORING AND SUPPLY CHAIN VISIBILITY FOR PFIZER-BIONTECH COVID-19 VACCINE'S GLOBAL DISTRIBUTION

Controlant | December 16, 2020

news image

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant ...

Read More

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

BioSpace | March 27, 2020

news image

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More

MEDICAL

Veeva Systems | September 24, 2021

news image

CONVATEC SELECTS VEEVA VAULT CDMS FOR STUDY OF BIOMARKERS IN WOUND INFECTIONS

Veeva Systems announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic disease, has selected Veeva Vault CDMS , which will provide electronic data entry ( EDC ), coding and data cleaning for its upcoming study on wound infection detection. ConvaTec and its partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers:...

Read More

Labiotech.eu | January 27, 2020

news image

UK STARTUP SNAPS UP POTENTIAL UNIVERSAL CANCER IMMUNOTHERAPY

The cancer vaccine developer Ervaxx has licensed a preclinical-stage ‘universal’ cancer immunotherapy based on the recent discovery of a new strain of immune T-cells at Cardiff University, UK. Last week, a team led by researchers at Cardiff University published research about T-cells capable of hunting a wide range of cancers including leukemia and melanoma. Experiments in vitro and in mice suggested that these T-cells could form the basis of a ‘universal’ cancer immunoth...

Read More

MEDICAL

Controlant | December 16, 2020

news image

CONTROLANT NOW PROVIDING MONITORING AND SUPPLY CHAIN VISIBILITY FOR PFIZER-BIONTECH COVID-19 VACCINE'S GLOBAL DISTRIBUTION

Controlant, an leader in real-time supply chain monitoring and perceivability technologies for vigorously controlled ventures, for example, pharmaceuticals and life sciences and food and drink areas, today reported it is giving observing and Supply Chain Visibility administrations to Pfizer, comparable to the conveyance of Pfizer's mRNA-based Pfizer-BioNTech COVID-19 vaccine's worldwide circulation. In addition to the visibility and monitoring arrangements that Controlant ...

Read More

BioSpace | March 27, 2020

news image

CG ONCOLOGY ANNOUNCES LICENSE AND COMMERCIALIZATION AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD. FOR CG0070 IN JAPAN AND OTHER ASIAN COUNTRIES

CG Oncology, Inc. has announced today an exclusive license, development and commercialization agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") for its oncolytic immunotherapy drug CG0070 for Japan, South Korea, Taiwan and other Asian countries with the exception of China. CG Oncology has completed an investigational Phase 2 study of CG0070 in the United States in patients with BCG-unresponsive, non-muscle-invasive bladder cancer (NMIBC). In addition, CG Oncology is studying th...

Read More